TORRINGTON, Conn., Oct. 8, 2025 /PRNewswire/ — Therap Services, the national leader in HIPAA-compliant electronic documentation solutions for organizations in the Long-Term Services and Supports (LTSS), Home and Community Based Services (HCBS), and other human services industries, has updated its Medication Administration Record (MAR) module. This update introduces enhancements to both the Daily MAR and legacy MAR module, helping agencies improve clarity, accuracy, and navigation while preparing for the transition to the new MAR platform.
Enhanced Clarity and Accuracy in MAR
The Daily MAR now features updated color codes for MAR legends, along with a clearer separation of “Missed” and “Refused” documentation. Navigation improvements include renaming “Expand” to “Detail Entry” in Quick Entry and QR/Barcode Entry windows. Time-sync alerts and validation messages help ensure accurate medication documentation, while MAR PDFs now reflect updated legends for consistency.
Preparing for the Future of MAR
Legacy MAR updates include refreshed visuals, separated legends, and a banner reminding users that the module will become read-only on November 30, 2025. These updates ensure users are ready for a smooth transition to the Daily MAR while maintaining clear, reliable documentation.
Why This Update Matters
This update reinforces Therap’s commitment to delivering intuitive, practical tools that support compliance, accuracy, and efficiency in medication administration.
Learn More
About Therap Services
Therap’s comprehensive and HIPAA-compliant software is used in human services settings for documentation, communication, reporting, EVV and billing.
https://www.therapservices.net/
SOURCE Therap Services
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…